Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26113878 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2TDP1ALDH1A1POLBHTT | |
| SCHEMBL15132866 | 0.83 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1POLBHTT | |
| SCHEMBL23275726 | 0.82 | KMT2A (0.62) | SMN1; SMN2ALDH1A1HTTPDE2AKDM4E | |
| SCHEMBL16945880 | 0.82 | ALDH1A1 (0.55) | HRH3SMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL23430815 | 0.81 | HRH3 (0.63) | HRH3SMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL1535757 | 0.79 | SMN1; SMN2 (0.69) | HRH3SMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL3381044 | 0.79 | ESR1 (0.55) | HRH3SMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL4146260 | 0.77 | HRH3 (0.57) | HRH3SMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL24746120 | 0.77 | ALDH1A1 (0.72) | HRH3SMN1; SMN2ALDH1A1POLBHTT | |
| SCHEMBL790908 | 0.77 | HRH3 (0.52) | HRH3SMN1; SMN2ALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | HRH3 64/4885SMN1; SMN2 2397/4885TDP1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.